Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
about
Emergence of linezolid resistance in a clinical Staphylococcus capitis isolate from Jiangsu Province of China in 2012.Selective pharmacologic inhibition of a PASTA kinase increases Listeria monocytogenes susceptibility to β-lactam antibioticsIdentification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid contentEmergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, OhioUse of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series.Txe, an endoribonuclease of the enterococcal Axe-Txe toxin-antitoxin system, cleaves mRNA and inhibits protein synthesisCeftaroline in complicated skin and skin-structure infections.Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus.Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy.Emergence of daptomycin-resistant VRE: experience of a single institution.Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infectionsNewer developments in the treatment of Gram-positive infections.Vancomycin-resistant enterococcal urinary tract infections.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center.Streptococcus mitis and S. oralis Lack a Requirement for CdsA, the Enzyme Required for Synthesis of Major Membrane Phospholipids in Bacteria.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.What's New in the Treatment of Enterococcal Endocarditis?Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocarEvaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents.Vascular surgical antibiotic prophylaxis study (VSAPS).Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: an emerging threat.Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11 year period.Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study.Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus
P2860
Q33586058-C01817D4-17AC-4F25-89D5-88E4D4FDC945Q34058063-4834B249-00D3-444C-AEF4-DEBD2320A502Q34058360-4C92D5B4-028A-4B23-9594-D71021D6B541Q34187667-94DFCD41-AA03-48F1-B2CD-AB32C7CEFA07Q34405922-39194342-9FAD-48E2-99F5-3CC101430D05Q34737606-9F4EF3A8-0388-496D-8A15-7E1F7516B4F5Q34835269-F0DF63B6-1801-4B24-880B-C43254667F4BQ34954571-F8732F33-8C06-442E-A4B0-1453904AC033Q35715381-A8BB8552-33EA-4547-AB52-BB508E2F8541Q36217683-5887FC8B-26D5-413F-8DA9-15872C081EBCQ36738730-1FADD9A7-5E9D-4370-B913-22834719FC3CQ36914057-3BD1AD5B-A611-4A73-AFFC-AF484CAEC009Q36927625-A86E7FCF-5906-4904-9FE5-7C4D84C5D66AQ37636151-DF7E2F68-6D8A-4D69-BDB2-0A82C622AD9EQ37802885-E889A9DB-2554-4257-8EA6-A48006FF140FQ38263421-37E45D50-BA3A-40E5-9E71-040BB809C9B9Q38286351-BBE8D2B5-D46B-4258-A6CF-451E6FDD6E21Q38552573-1288958C-3E16-4FEC-A639-DA29D213E630Q38692072-61AC5B65-2F3D-49DF-9F83-6282110258D6Q38741373-F812F194-6336-4940-AE7B-8FDC2C4BE966Q38949288-2A95206F-7F8D-4EC4-8953-F0197A3ECF35Q40254524-D108FFC2-E5F3-4335-85C8-C23381789ED5Q41368979-691F1F92-EFD3-4744-B077-3FF99FDF6E3EQ41520373-6ED766DF-764B-42C2-BE2F-80996F0711E5Q41570351-0C12BAB2-11FD-4502-B4DA-1E2B89764705Q42131112-67D23CA4-CD5E-49DF-9510-41EC38F30E59Q42189998-2A04E38C-321B-4DEC-9BF3-8CF41CC476C1Q42217460-B0C8585C-226B-4F3C-9BD8-D25A40ADA131Q42363645-9C5180F3-6C45-4C61-8884-A6AC5709200DQ42372253-260C5A70-CCE3-4433-8F40-E8A61A0E1FA0Q42950341-F988DE04-B5F8-498B-813F-620D79FAC7BAQ43106836-447C3DC5-B9EC-462D-9929-58D1F5A90E3DQ44579110-4CE34DAE-7449-4939-B3FC-F9C5A74FF8CFQ44773902-3BDD3993-86D5-4176-953A-62DE0870D7F9Q44979977-BCD0AAAC-B0DE-4FFB-A203-C54774395903Q45013453-A209D5ED-D669-43B8-A181-A1D95C3C91E4Q51042109-1DCC94B8-16FE-4F2D-A697-FC31F5B2CC7CQ53654914-06975BB5-E3AB-43B9-8E98-EF75BEA5F2BAQ57480754-77553A19-AEE1-42C6-AB13-4830F6FCFAAE
P2860
Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Antimicrobial susceptibility o ...... veillance Program (2007-2008).
@en
Antimicrobial susceptibility o ...... aptomycin Surveillance Program
@nl
type
label
Antimicrobial susceptibility o ...... veillance Program (2007-2008).
@en
Antimicrobial susceptibility o ...... aptomycin Surveillance Program
@nl
prefLabel
Antimicrobial susceptibility o ...... veillance Program (2007-2008).
@en
Antimicrobial susceptibility o ...... aptomycin Surveillance Program
@nl
P1476
Antimicrobial susceptibility o ...... veillance Program (2007-2008).
@en
P2093
Ronald N Jones
P304
P356
10.1016/J.DIAGMICROBIO.2009.06.016
P577
2009-10-01T00:00:00Z